In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (  = 1,211). Contezolid demonstrated potent activity against (MIC , 0.5/1 mg/liter), coagulase-negat...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2020-10, Vol.64 (11)
Main Authors: Carvalhaes, Cecilia G, Duncan, Leonard R, Wang, Wen, Sader, Helio S
Format: Article
Language:English
Subjects:
Epidemiology and Surveillance
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673
cites cdi_FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673
container_end_page
container_issue 11
container_start_page
container_title Antimicrobial agents and chemotherapy
container_volume 64
creator Carvalhaes, Cecilia G
Duncan, Leonard R
Wang, Wen
Sader, Helio S
description Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (  = 1,211). Contezolid demonstrated potent activity against (MIC , 0.5/1 mg/liter), coagulase-negative (MIC , 0.25/0.5 mg/liter), spp. (MIC , 0.5/1 mg/liter), and streptococci (MIC , 1/1 mg/liter). Moreover, methicillin-resistant and vancomycin-resistant isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.
doi_str_mv 10.1128/AAC.01195-20
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7577137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2432855910</sourcerecordid><originalsourceid>FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673</originalsourceid><addsrcrecordid>eNp1kcFu1DAQhi0EokvLjTPysZVIseM4Ti5Iq1VpVyq0Ki3iZjnOuHWV2FvbWbE8Cw_bZLdUcOBkjf35G838CL2j5JjSvPo4ny-OCaU1z3LyAs0oqaus5HX5Es0IKcusqEixh97EeE_GmtfkNdpjuRAV5_kM_V46_N2m4PFcJ7u2aYOVa_GlT-D0BnuD0x3gr34NHb74qX75zrbWeQd44V2CbY0Pv1z9yJZH-BpigharW2VdTPg0qD679NGO4pHvrLNadXgZfacSRGyC77f6G2enf9_S9nrqfzIEv4ID9MqoLsLbp3Mf3Xw-uV6cZecXp8vF_DxTBa1SVjW84MB1UdbcNCBMKVihirYB0-ZUG9WYmgjWaEMKqrlitFFQUwpMUM5GeB992nlXQ9NDq8GloDq5CrZXYSO9svLfF2fv5K1fS8GFoGwSHD4Jgn8Yxi3I3kYNXacc-CHKvGD5uO-akhH9sEN18DEGMM9tKJFToHIMVG4DlfmEH-1wFftc3vshuHET_2Pf_z3Gs_hP2uwRNluq2Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2432855910</pqid></control><display><type>article</type><title>In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe</title><source>Open Access: PubMed Central</source><source>ASM_美国微生物学会期刊</source><creator>Carvalhaes, Cecilia G ; Duncan, Leonard R ; Wang, Wen ; Sader, Helio S</creator><creatorcontrib>Carvalhaes, Cecilia G ; Duncan, Leonard R ; Wang, Wen ; Sader, Helio S</creatorcontrib><description>Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (  = 1,211). Contezolid demonstrated potent activity against (MIC , 0.5/1 mg/liter), coagulase-negative (MIC , 0.25/0.5 mg/liter), spp. (MIC , 0.5/1 mg/liter), and streptococci (MIC , 1/1 mg/liter). Moreover, methicillin-resistant and vancomycin-resistant isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.</description><identifier>ISSN: 0066-4804</identifier><identifier>EISSN: 1098-6596</identifier><identifier>DOI: 10.1128/AAC.01195-20</identifier><identifier>PMID: 32778552</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Epidemiology and Surveillance</subject><ispartof>Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)</ispartof><rights>Copyright © 2020 American Society for Microbiology.</rights><rights>Copyright © 2020 American Society for Microbiology. 2020 American Society for Microbiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673</citedby><cites>FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673</cites><orcidid>0000-0001-7022-6644</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.asm.org/doi/pdf/10.1128/AAC.01195-20$$EPDF$$P50$$Gasm2$$H</linktopdf><linktohtml>$$Uhttps://journals.asm.org/doi/full/10.1128/AAC.01195-20$$EHTML$$P50$$Gasm2$$H</linktohtml><link.rule.ids>230,314,725,778,782,883,3177,27907,27908,52734,52735,52736,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32778552$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carvalhaes, Cecilia G</creatorcontrib><creatorcontrib>Duncan, Leonard R</creatorcontrib><creatorcontrib>Wang, Wen</creatorcontrib><creatorcontrib>Sader, Helio S</creatorcontrib><title>In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe</title><title>Antimicrobial agents and chemotherapy</title><addtitle>Antimicrob Agents Chemother</addtitle><addtitle>Antimicrob Agents Chemother</addtitle><description>Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (  = 1,211). Contezolid demonstrated potent activity against (MIC , 0.5/1 mg/liter), coagulase-negative (MIC , 0.25/0.5 mg/liter), spp. (MIC , 0.5/1 mg/liter), and streptococci (MIC , 1/1 mg/liter). Moreover, methicillin-resistant and vancomycin-resistant isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.</description><subject>Epidemiology and Surveillance</subject><issn>0066-4804</issn><issn>1098-6596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp1kcFu1DAQhi0EokvLjTPysZVIseM4Ti5Iq1VpVyq0Ki3iZjnOuHWV2FvbWbE8Cw_bZLdUcOBkjf35G838CL2j5JjSvPo4ny-OCaU1z3LyAs0oqaus5HX5Es0IKcusqEixh97EeE_GmtfkNdpjuRAV5_kM_V46_N2m4PFcJ7u2aYOVa_GlT-D0BnuD0x3gr34NHb74qX75zrbWeQd44V2CbY0Pv1z9yJZH-BpigharW2VdTPg0qD679NGO4pHvrLNadXgZfacSRGyC77f6G2enf9_S9nrqfzIEv4ID9MqoLsLbp3Mf3Xw-uV6cZecXp8vF_DxTBa1SVjW84MB1UdbcNCBMKVihirYB0-ZUG9WYmgjWaEMKqrlitFFQUwpMUM5GeB992nlXQ9NDq8GloDq5CrZXYSO9svLfF2fv5K1fS8GFoGwSHD4Jgn8Yxi3I3kYNXacc-CHKvGD5uO-akhH9sEN18DEGMM9tKJFToHIMVG4DlfmEH-1wFftc3vshuHET_2Pf_z3Gs_hP2uwRNluq2Q</recordid><startdate>20201020</startdate><enddate>20201020</enddate><creator>Carvalhaes, Cecilia G</creator><creator>Duncan, Leonard R</creator><creator>Wang, Wen</creator><creator>Sader, Helio S</creator><general>American Society for Microbiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7022-6644</orcidid></search><sort><creationdate>20201020</creationdate><title>In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe</title><author>Carvalhaes, Cecilia G ; Duncan, Leonard R ; Wang, Wen ; Sader, Helio S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Epidemiology and Surveillance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carvalhaes, Cecilia G</creatorcontrib><creatorcontrib>Duncan, Leonard R</creatorcontrib><creatorcontrib>Wang, Wen</creatorcontrib><creatorcontrib>Sader, Helio S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Antimicrobial agents and chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carvalhaes, Cecilia G</au><au>Duncan, Leonard R</au><au>Wang, Wen</au><au>Sader, Helio S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe</atitle><jtitle>Antimicrobial agents and chemotherapy</jtitle><stitle>Antimicrob Agents Chemother</stitle><addtitle>Antimicrob Agents Chemother</addtitle><date>2020-10-20</date><risdate>2020</risdate><volume>64</volume><issue>11</issue><issn>0066-4804</issn><eissn>1098-6596</eissn><abstract>Contezolid, a new oxazolidinone antibacterial agent currently in development for the treatment of skin and skin structure infections, was susceptibility tested against Gram-positive clinical isolates (  = 1,211). Contezolid demonstrated potent activity against (MIC , 0.5/1 mg/liter), coagulase-negative (MIC , 0.25/0.5 mg/liter), spp. (MIC , 0.5/1 mg/liter), and streptococci (MIC , 1/1 mg/liter). Moreover, methicillin-resistant and vancomycin-resistant isolates were all inhibited by contezolid at ≤1 mg/liter. These results support the clinical development of contezolid.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>32778552</pmid><doi>10.1128/AAC.01195-20</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7022-6644</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0066-4804
ispartof Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)
issn 0066-4804
1098-6596
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7577137
source Open Access: PubMed Central; ASM_美国微生物学会期刊
subjects Epidemiology and Surveillance
title In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T04%3A40%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vitro%20Activity%20and%20Potency%20of%20the%20Novel%20Oxazolidinone%20Contezolid%20(MRX-I)%20Tested%20against%20Gram-Positive%20Clinical%20Isolates%20from%20the%20United%20States%20and%20Europe&rft.jtitle=Antimicrobial%20agents%20and%20chemotherapy&rft.au=Carvalhaes,%20Cecilia%20G&rft.date=2020-10-20&rft.volume=64&rft.issue=11&rft.issn=0066-4804&rft.eissn=1098-6596&rft_id=info:doi/10.1128/AAC.01195-20&rft_dat=%3Cproquest_pubme%3E2432855910%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a418t-8b545e5c4695fbe7f6734a4dbefd21cfabf9073bcf041c5a31bae911e37153673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2432855910&rft_id=info:pmid/32778552&rfr_iscdi=true